Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by RPINVESTOR1on Jan 27, 2023 12:59pm
108 Views
Post# 35250460

RE:RE:RE:RE:RE:RE:RE:market CRAZYNESS

RE:RE:RE:RE:RE:RE:RE:market CRAZYNESSBluemoons20:-

I am sure that they are still owing some creditors. L. Buckler may have agreed to delay some monthly payments as well. I think it is also going to cost them a fair bit of money to get him off the payroll.

The last 2 private placements just show me one thing - GREED! The insiders are getting shares at prices they could never dream of getting on the open market ..... and they have the nerve to throw in a 1/2 warrant sweetner to the mix at a very low price. I hope that any sale of Replicel involves an arms length transaction, otherwise the small investors will be screwed!

On another topic, I have not seen Lee Buckler mentioned in these private placements. If he has not participated, I find this remarkable. I can see why it was so difficult over the past number of years to attract partners. Entering into a deal with a CEO who only has a couple hundred dollars of equity in his own company is not a smart move. Wish I had thought about this years ago when I first started to buy shares in Replicel!       
<< Previous
Bullboard Posts
Next >>